Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory

Cannara Announces Graduation to the Toronto Stock Exchange

By The Northwire Desk — AI Analysis Feb 26, 2026 · 08:00 LOVE · 1.78 Cannara Biotech Inc.
LOVE · Price

Executive Summary

  • Cannara Biotech received final approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange, with trading on the TSX commencing March 2 2026 under ticker “LOVE”.
  • The company will be delisted from the TSXV on the same date and will open the market at the TSX on March 17 2026 as a celebratory event.
  • TD Cowen initiated coverage of Cannara, issuing a research report dated February 24 2026.

Key Details

  • Uplisting Approval: Final regulatory approval granted for transfer from TSXV to TSX.
  • Trading Commencement: TSX trading begins at market open on March 2 2026 (ticker “LOVE”).
  • Delisting Date: Shares will be removed from the TSXV effective March 2 2026.
  • Market Opening Honor: Cannara will open the TSX trading floor on March 17 2026 to mark the milestone.
  • Analyst Coverage: TD Cowen initiated coverage as of February 24 2026; research report available through TD Cowen platform (disclaimer that opinions are solely those of TD Cowen).

Notable Quotes

“Graduating to the TSX represents a significant milestone in Cannara's evolution as a public company,” said Zohar Krivorot, Founder and CEO.
“This achievement enhances our market visibility and liquidity while broadening our accessibility to institutional investors.”

Read the original news release →

More from Cannara Biotech Inc.

May 06, 2026 · 08:00

Cannara Consolidates Quebec Operations

M&A / Property Apr 14, 2026 · 07:07

SEDAR Interim Financial Statements

None Apr 14, 2026 · 07:00

Cannara Biotech Confirms Profitability Amidst Revenue Growth Deceleration

Earnings Apr 07, 2026 · 07:00

Cannara Biotech Inc.

Earnings Feb 04, 2026 · 17:47

Cannara Biotech closes $6.3-million private placement

Financings Feb 04, 2026 · 08:00

Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share

Financings